RT Journal Article SR Electronic T1 The December 2019 New Corona Virus Disease (SARS-CoV-2) Outbreak: A Behavioral Infectious Disease Policy Model JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.04.13.20063610 DO 10.1101/2020.04.13.20063610 A1 Jeroen Struben YR 2020 UL http://medrxiv.org/content/early/2020/04/17/2020.04.13.20063610.abstract AB Since the December 2019 coronavirus (SARS-CoV-2) outbreak began to spread globally, significant variation has emerged and sustained among countries’ responses and successes. We outline a flexible behavioral, dynamic, and sectorial epidemic model of both virus transmission dynamics and endogenous policy and citizen responses. The model allows exploring distinct policy interventions, comprising general and targeted testing and social contact reduction efforts. Calibrating the model to the ongoing SARS-CoV-2 pandemic at the level of continents, we demonstrate how the early and extensive buildup of testing and social contact reduction efforts interplay to suppress the outbreak. Further, through a synthetic dynamic analysis of virus resurgence and of stratified case severity across population segments, we show the importance of targeted approaches for effectively reducing the multifaceted impacts of the outbreak. Finally, to aide critical collective involvement of policymakers, volunteers, citizens, and media for successfully controlling outbreaks as these, a version of the model is also available as a free web-based management flight simulator.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno external funding was received.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data is publicly available (sources have been referenced in the document.)